Purchase Order 75N95025P00047
Award Date
12/5/24
Potential Completion Date
12/4/25
Potential Value
$47K
Federal Agency
National Institute on Drug Abuse
Awardee
Insphero Inc.
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Brunswick, ME 04011, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $34,276.75, was issued by the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services (HHS), to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies and in vitro models. The contract is for the delivery of 3D liver microtissues composed of human primary hepatocytes, liver endothelial cells, and Kupffer cells, which will be used by NIDA's 3D Tissue Bioprinting Laboratory...
This is a $90,414 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies and in vitro models. The contract is for a Liver Assay in Liver Spheroids to evaluate the toxicity of short interfering RNA (siRNA) and antisense oligonucleotides (ASOs), which are increasingly being used as...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, awarded a $75,000.00 firm-fixed-price purchase order to Insphero Inc., a foreign-owned for-profit manufacturer of advanced 3D cell culture products. The contract is for safety assessment studies using Insphero's human, mouse, and rat 3D liver spheroid models to evaluate drug-induced liver injury (DILI) as part of the DILIPLUS assay program. This contract...
Insphero, Inc. has been awarded a firm fixed price purchase order valued at twenty-two thousand eight hundred dollars from the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences. The contract calls for Insphero to provide 3D liver microtissues composed of human primary hepatocytes and liver cells for drug testing and safety assessments. Insphero will deliver the 3D liver spheroids to support drug-induced liver injury assays...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, has awarded a $96,829.63 firm-fixed-price purchase order to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies. The contract is for a Transcriptomics study - RNA-seq in Liver Spheroids Phase One, with the purpose of evaluating the safety and liver toxicity of candidate antisense oligonucleotides using a 3D liver microtissue...
This $25,100 firm-fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA) to Lifenet Health, a non-profit organization and manufacturer of regenerative medicine products, to conduct 3D liver spheroid assays for pharmacogenomics-based prediction of drug-induced liver injury (DILI). The award has a period of performance through September 29, 2025 and was not set aside for any particular business type. Lifenet Health is a specialized provider of human tissues and...
This purchase order contract was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Life Technologies Corporation for the delivery of 50 vials of human spheroid-qualified hepatocytes. As described in the original solicitation, these liver cells will support the National Institute on Drug Abuse's Antiviral Program for Pandemics by enabling the continued identification of direct-acting antivirals and development of microphysiological systems...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Life Technologies Corporation, a manufacturer of scientific instruments, reagents, and consumables. The $24,262.29 contract is for the delivery of primary human hepatocytes, which are a critical reagent used in biomedical research supported by NCATS. This contract is not associated with any set-aside...
This is a $24,900 firm-fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences to 3Dnamics Inc., a biotechnology company that provides stem cell engineering technology and related services. The contract is for the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte organoids, which are three-dimensional cell cultures that model liver tissue. This work supports...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $45,717 firm fixed price purchase order to Xenotech LLC, doing business as Sekisui-Xenotech, for the provision of cryopreserved human, mouse, and rat hepatocytes. The solicitation sought these hepatocytes for use in drug metabolism experiments to support the National Institute on Drug Abuse's malaria research project and understand drug metabolism in...